What to know before you play the Legend of Zelda: Tears of the Kingdom!
WEBWIRE – Wednesday, May 17, 2023
The wait is overthe Legend of Zelda: Tears of the Kingdom game is finally here! Theres a lot to discover, and we want you to put your best boot forward when you set out in Hyrule.
Lets start with a few important tips before you start playing. But dont worry, well stay away from any spoilers. Think of this article as a way to help get in the right mindset before playing.
Oh! And well be bringing you more tips articles in the coming weeks, so be sure to keep an eye on the news feed.
Tip 1: Unlearn what youve learned
Yeah, this may sound like something youd be told from a martial arts master, but hear us out. Whether youve played hundreds of hours of The Legend of Zelda: Breath of the Wild or are brand new to the series, your experience level doesnt really matter when it comes to this game.
While things youve done in previous games may still work, you have a wide variety of options in this sequel. Sure, you can still fight enemies with a stick or you can fuse a boulder to your stick and jump on springboards to bonk enemies on the head. Sure, you can climb your way out of a hole or you can use the Ascend ability to travel through the ceiling and get where you need to go.
Tip 2: Try everything
This game encourages you to try new things throughout. From traveling around Hyrule to solving puzzles, there are multiple ways to overcome problems you run into. The joy comes from trying out crazy ideas that end up working.
Oh, and if something isnt working out the way you want, take a moment and try something else. Some players find joy in attempting a difficult jump over and over. Others would rather build a bridge. Experimentation is the heart of this gameeven if a situation doesnt go as expected, you may stumble upon something that will help you later.
Tip 3: Get some perspective
When you enter a new area, find a tall vantage point and scope out your surroundings. Youll find all sorts of stuffenemies, chests, materials, objects or terrain that will help in fights, and more. Believe us, it will be easier to do this before enemies spot you. Speaking of
Tip 4: Prepare for fights beforehand
Look, you dont have to do thiswere (sometimes) fond of charging into the middle of things while screaming and wildly waving our arms too. But if you want to use the Fuse ability to make strong weapons or Ultrahand to build a makeshift missile turret, you may want to do that before Bokoblins are trying to smack you around. A little prep time can go a long way.
Tip 5: Use your words
This wont work on enemies (at least the ones weve tried) but try talking to the more peaceful characters out there! In particular, characters called Constructs may give you helpful tips about the area.
Tip 6: Play it your way
OK, this is probably the most important tip. Sure, Link is the character in the game, but remember that you are the hero here. You are saving Hyrule. And you can do it how you want to! Play around with everything you get your hands on, because theres room for massive creativity (and shenanigans) in this game.
With that said, dont worry about not being creative enough. Everyone is creative on some level, and a part of creativity is giving yourself permission to try new things. We all play in different waysmessy ways, elaborate ways, unexpected ways, and silly ways that have no purpose other than to see what happens. Dont worry about playing the game the right way because its up to you how you want to approach obstacles. If something works in the end, its a success. If it doesnt, did you at least get a chuckle out of it?
Tip 7: Share the knowledge
And finally, creativity comes alive when you share what you know and get inspired by others. Talk to your friends to see what theyve tried. Maybe find out what other people have done. You may be surprised what ends up inspiring you!
Alrighty, thats all for now. Be on the lookout for our next tips article which will cover the four new abilitiesFuse, Ultrahand, Ascend, and Recall. You can also buy the game using the link below.
Have fun out there!
The Legend of Zelda: Tears of the KingdomRegular Price:$69.99Nintendo Switch
Learn more
Shenzhen Macrolux Medical Technology Co., Ltd. (hereinafter referred to as “Macrolux”) recently announced the completion of its Series A round by securing nearly CNY100 million, which is led by Legend Capital. Regarding this fundraising round, ZHANG Weiqiang, General Manager of Macrolux, said: “I’d like to extend my sincere gratitude to all the investors for their trust in Macrolux. Disposable electronic endoscopes are an early market experiencing rapid growth. With years of concentrating on the product development and technological innovation of disposable endoscopes, Macrolux has formed strong competitiveness in many aspects and aims to introduce solutions to the world that better meet customer needs relying on our ten more years of technology accumulation in the industry.” Joe ZHOU, Managing Director of Legend Capital, said: “Legend Capital has focused on endoscopic diagnosis and treatment, which is a development direction of minimally invasive medical treatment. It is noticed that disposable endoscopes have solved the sore points of traditional medical devices in multiple application scenarios and have begun to penetrate rapidly in recent years. All the functional teams of Macrolux are experienced and have worked in a balanced way for a long time and shared complete commercialization experience from scratch to impressive performance. We are honored to cooperate with the team and look forward to the company’s innovative series of products accelerating penetration into clinical applications to benefit patients globally.” Legend Capital has long been paying attention to the investment in the field of medical devices and diagnostics with a focus on three major themes: first, major diseases, especially the unmet clinical needs of chronic diseases; second, the first and uniqueness in technology, which enables a company to become or have the potential to become a leading player in subdivided industries; the third is the “device +” investment opportunities brought by the integration of medical devices and interdisciplinary technologies such as AI, IoT and Big Data. At present, Legend Capital has invested in numerous leading companies in the subdivided industries, including Careray Digital Medical Technology (688607.SH), Axonics (AXNX), New Horizon Health (06606.HK), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Berry Genomics (000710.SZ), Aohua Photoelectricity Endoscope (688212.SH), Chemclin Diagnostics (688468.SH), Bio-heart Biological (02185.HK), STAR Sports Medicine, ET Healthcare, GKHT Medical Technology, Hailai Xinchuang Medical Technology, Yeasen Biotechnology, and Dearer Medical. About Legend Capital Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Legend Capital Portfolio Company Bespin Global, a Korea-headquartered cloud services company, has recently completed its Series D round financing of USD100 million, which will be used mostly for acquisitions. John HanJoo Lee, CEO and co-founder of Bespin Global said, “By combining forces with e& enterprise in the METAP region, we are bringing much needed cloud managed services to the region where cloud adoption is about to explode. e& enterprise has deep customer relationships and the trust of its customers and Bespin Global has the deep cloud management capabilities. Together, we can accelerate cloud adoption in the region. Additionally, we welcome e& as our shareholder. It’s a clear validation of our track record as a trusted cloud managed services provider on the global stage.” Bespin Global helps its customers in their digital transformation by providing cloud migration, cloud management and related SaaS offerings. It is the first multi-cloud managed service provider in East Asia with partnerships with Amazon Web Services, Microsoft Azure, Google Cloud, Aliyun, Tencent Cloud, and Naver Cloud. The company has offices in 9 countries including Korea, China, Japan, Singapore, Vietnam, Indonesia, the US, UAE, and Saudi Arabia. It has over 1,700 customers which range from large enterprises to fast growing startups. Legend Capital led Bespin Global’s Series A financing in 2017, and continued to invest in the company’s Series B financing in 2019. As an early investor, Legend Capital has provided support and help to Bespin Global in global cooperation, enterprise management and subsequent financing, to promote Bespin Global’s development. In 2020, Legend Capital introduced Serverworks, a leading AWS Cloud integrator in Japan, to Bespin Global. The two companies established a joint venture in September 2021, entering the Japanese market officially. John HanJoo Lee, CEO and co-founder of Bespin Global said, “It was Legend Capital that first introduced us to the UAE investors that led to the successful funding round with e&. Many venture capital firms talk about adding value, but only a few actually do. Legend Capital continues to add value beyond just capital. We are so lucky to have such a great partner as our investor.” About Legend Capital Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as “GS Biotech”) officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital. The proceeds will be mainly used for the capacity expansion of core pipeline products 5-hydroxymethylfurfural (HMF), 2,5-furandicarboxylic acid (FDCA) and 2,5-tetrahydrofuran dimethanol (THFDM), and the continuous development of downstream derivatives. According to Dr. John Zhang, CEO of GS Biotech, the company has taken the development model of promoting the “two-wheel drive” of the dual track as an important strategic direction. On the one hand, the company has completely solved the problems of HMF cost and raw material sources; its original HMF continuous production process, which completed the verification of multi-dimensional cost reduction measures, has greatly reduced the production cost and effectively improved the efficiency, and it is expected that the production cost of HMF will be controlled within RMB10,000 per ton in the future three years from the extraction of non-grain raw material sources to the iterative path of the production process and to the planning of expanding production capacity. Meanwhile, the company has also reserved more than 20 kinds of high-value-added monomers and is simultaneously promoting the verification of the application of each monomer in the terminal market. Moreover, GS Biotech established a joint venture, Xinshengtai Materials, with an AI-powered drug R&D unicorn company XtalPi Inc to focus on using AI technology to accelerate the reverse design of derivatives and improve the development efficiency of downstream derivatives to further accelerate its high-efficiency and accurate market development process. On the other hand, the company has also made significant progress in the design, R&D and industrialization of degradable new materials. The new biodegradable plastic PEOX, another important pipeline of the company, has completed the 150L pilot scale experiment and obtained market terminal verification. The performance indicators of PEOX can be compared with PGA and the price of the terminal product will be approximately RMB10,000/ton after the large-scale production. With the special performance of the product and the support of policies, many leading enterprises in the industry are negotiating with the company to sign an underwriting agreement to apply PEOX in the field of disposable packagings such as agricultural mulch, plastic bags, straws, and lunch boxes. Legend Capital said: “Under the background of China’s strategy in carbon peaking and carbon neutrality and the pursuit of sustainable energy development, petroleum-based chemical materials will gradually be replaced by bio-based materials, which are produced from sustainable resources. HMF is an important bio-based platform compound with great potential for downstream derivatives. GS Biotech has pioneered the HMF continuous production process globally and realized the large-scale and low-cost production of HMF. It has opened the entire industry chain from upstream core monomers to terminal applications and innovatively introduced AI and high-throughput machine synthesis technology into the development of downstream derivative products. The core team of GS Biotech graduated from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences. With nearly 20 years of research foundation and industrialization experience in the field of biomass catalytic conversion, GS Biotech has shown strong capabilities in continuous R&D, production management, and resource integration. Legend Capital has long focused on technology investments linked to carbon peaking and carbon neutrality, and we look forward to working with GS Biotech to promote technological change in the field of bio-based materials.” As an interdisciplinary subject of information science, life science and material science, synthetic biology and bio-based materials have always been the direction that Legend Capital has paid close attention to in the field of carbon-neutral technology investment. Legend Capital’s investments in the carbon-neutral field focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power, and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others; in the field of synthetic biology and bio-based materials, Legend Capital has invested in many outstanding companies such as Giant Biogene (02367.HK), GS Biotech, Huili Biotech, and Tidetron Bioworks Technology. About Legend Capital Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. This round of financing will facilitate ClinBrain to continuously deepen its expertise in the field of healthcare big data, explore the deep integration of big data and AI in the healthcare industry, promote the R&D of underlying technologies and scenario-based applications, and accelerate the promotion of industrial digital and intelligent upgrading. At the beginning of its establishment in 2013, ClinBrain realized that healthcare, as a data-intensive and knowledge-intensive industry, is inseparable from the support of data, no matter in clinical services, operations management or medical research. ClinBrain has been committed to the direction of data governance and intelligent application of hospitals. By leveraging years of its industry experience and technical capabilities, the company has made breakthroughs in many fields, such as collecting data from hospital business systems without an interface, effectively identifying the data structure of complex business systems, effectively cleaning the business data of different versions and different manufacturers, forming effective and practical data quality rules to improve the data quality of hospitals, and conducting structured processing of unstructured data such as medical records and pathology. Moreover, with its powerful natural language processing (NLP) capabilities and robust rule and knowledge base, including more than 3900 data cleaning and quality rules embedded and tens of millions of medical concept term relationships accumulated, ClinBrain is also capable of automatically identifying the data structure of each version of more than 500 business manufacturers and realizing high-quality data cleaning and structured processing of unstructured data. LIU Huanchun, Chairman of ClinBrain, said, “Under the complex and volatile economic background and the ongoing pandemic situation, the recognition by many investors has reflected the market position, technological level and value of ClinBrain. After this round of financing, ClinBrain will promote the company’s development to a new level by making further efforts in scientific and technological innovation and talent introduction.” Raymond CHEN, Co-chief Investment Officer of Legend Capital, said, “Healthcare big data is a key driver of the digital and intelligent transformation of the pharmaceutical industry, which is in line with the long-term megatrend of new healthcare infrastructure. As a leading healthcare big data enterprise in China, ClinBrain provides full-link solutions from data governance to medical scenario applications based on its rich industrial theoretical knowledge and practical experience. We are optimistic that ClinBrain will create a new development form in healthcare big data by continuously expanding more products and customer application scenarios.” About Legend Capital Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital).
Led by Legend Capital, Macrolux Completes Nearly CNY100 million Series A Round
Founded in October 2020 and headquartered in Shenzhen, Macrolux is a medical technology company focusing on innovative solutions for endoscopic interventional diagnosis and treatment. Macrolux’s founding team is formed from experts from leading medical device companies in China and has more than a decade of experience in product development, global marketing and the production management of endoscopes and minimally invasive surgical devices. With a vision of detecting diseases earlier and offering patients better treatments, Macrolux is committed to providing the world with endoscopic interventional diagnosis and treatment solutions covering departments including urology, respiration, and digestion by leveraging its engine for innovation-driven development.
Topic: Press release summaryLegend Capital Portfolio Company Bespin Global Completes USD100m Series D Financing
Concurrent with the investment, the investor, e& Enterprise, a leading digital services provider in UAE (formerly Etisalat Digital), and Bespin Global will form a joint venture that will serve customers in the Middle East, North Africa and Pakistan.
Topic: Press release summaryLed by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing
Founded in 2021 with the vision of “Biomass Change Lives”, GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain. The members of its founding team graduated from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and have nearly 20 years of research foundation and industrialization experience in the fields of biomass catalytic conversion and furan-based material design and development. At present, the R&D team building has also been completed from biomass, derivatives to polymers, which ensures the cutting-edge of the company’s product development and the availability of end products.
Topic: Press release summaryLed by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round
As a high-tech enterprise focusing on the healthcare big data intelligence platform, digitalized and intelligent application services, ClinBrain was shortlisted as the SDRI (specialized, refined, differential and innovative) “little giant” enterprise by the Ministry of Industry and Information Technology this year.
Topic: Press release summary
Ads
